Dr Federico Perche
Associate Editor: Federico Perche
During his PhD at the Centre for Molecular Biophysics (CBM, Orléans, France) with Dr. Midoux and Dr. Pichon, Federico Perche developed dendritic cell-targeted lipopolyplexes, achieving efficient transfection of splenic dendritic cells in vivo resulting in superior protection against melanoma growth over untargeted mRNA lipopolyplexes. Next, he did a first postdoctoral stay with Pr. Torchilin at the Center for Pharmaceutical Biotechnology and Nanomedicine (Northeastern University, Boston, USA). There he worked on stimuli-sensitive delivery systems for siRNA and drug (paclitaxel and doxorubicin) delivery. With his colleagues, they demonstrated triggered exposure of internalization motifs by two tumor environment stimuli: matrix metalloproteases, and hypoxia. He continued his training in Pharmaceutical Sciences by a second postdoctoral stay as Japanese Society for the Promotion of Science fellow with Pr. Kataoka and Dr Miyata at the Center for Nano Bio Integration (The University of Tokyo, Japan) where he worked on intrathecal delivery of an mRNA coding an anti-Aβ scFv for Alzheimer’s disease immunotherapy and on chloroquine conjugation to gold nanoparticles for improved siRNA activity.
He secured a permanent Researcher position at the CBM in 2016. His work focuses on intracellular delivery of RNA for anticancer vaccination and for bone regeneration. Using a reductionist approach combining molecular biology and drug delivery, he aims at mimicking RNA viruses’ mechanisms to improve the intracellular bioavailability of transfected RNA for improved activity.